Fiera Capital Corp Sells 39,338 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Fiera Capital Corp trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 3.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,257,964 shares of the company’s stock after selling 39,338 shares during the period. Fiera Capital Corp owned about 1.69% of SpringWorks Therapeutics worth $40,305,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. increased its position in SpringWorks Therapeutics by 49.0% during the 1st quarter. Russell Investments Group Ltd. now owns 170,047 shares of the company’s stock valued at $8,370,000 after purchasing an additional 55,893 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of SpringWorks Therapeutics by 48.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company’s stock valued at $202,318,000 after buying an additional 1,333,892 shares during the period. Vanguard Group Inc. increased its position in shares of SpringWorks Therapeutics by 8.2% during the first quarter. Vanguard Group Inc. now owns 6,529,325 shares of the company’s stock valued at $321,373,000 after buying an additional 492,783 shares during the period. D. E. Shaw & Co. Inc. raised its stake in SpringWorks Therapeutics by 16.9% in the second quarter. D. E. Shaw & Co. Inc. now owns 758,712 shares of the company’s stock worth $28,581,000 after buying an additional 109,865 shares in the last quarter. Finally, Seven Eight Capital LP bought a new stake in SpringWorks Therapeutics during the 2nd quarter valued at approximately $1,854,000.

SpringWorks Therapeutics Stock Performance

Shares of SWTX stock opened at $33.99 on Friday. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -7.67 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a one year low of $18.00 and a one year high of $53.92. The company’s 50-day moving average is $33.41 and its 200 day moving average is $37.54.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.58. The firm had revenue of $59.73 million for the quarter, compared to the consensus estimate of $34.42 million. SpringWorks Therapeutics’s revenue was up 59732900.0% on a year-over-year basis. During the same period last year, the business earned ($1.25) EPS. As a group, research analysts predict that SpringWorks Therapeutics, Inc. will post -3.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $76.00 target price on shares of SpringWorks Therapeutics in a research note on Wednesday, August 28th. Wedbush reissued an “outperform” rating and set a $77.00 price objective on shares of SpringWorks Therapeutics in a research report on Thursday. Finally, JPMorgan Chase & Co. upped their target price on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics presently has an average rating of “Buy” and an average price target of $68.50.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.